A new Office of Inspector General (OIG) data brief highlights potential weaknesses in CMS’ and Medicare Administrative Contractors’ (MAC) oversight of Part B outpatient drug billing.
Revenue integrity staff at physician offices must follow CMS billing guidelines for ITVISMA®, a new gene therapy drug approved to treat certain patients with spinal muscular atrophy.
Q: What should revenue integrity teams at short-term acute care hospitals keep in mind before analyzing Program for Evaluating Payment Patterns Electronic Report (PEPPER) findings?
Speaking at the Revenue Integrity Symposium (RIS) is an incredible opportunity for professionals looking to make their mark on the revenue integrity field. Submit your application to speak by January 11, 2027.
